Immunai

Transforming Drug Development Through AI-Powered Immune System Mapping

Immunai is a cutting-edge AI platform that decodes the immune system at unprecedented scale and resolution to facilitate the development of next-generation immune-related therapeutics. By mapping complex immune mechanisms and translating them into actionable insights, Immunai empowers biopharmaceutical companies and research institutions to make smarter decisions throughout the drug discovery and development journey.

Who It's For

Immunai partners with leading pharmaceutical companies like AstraZeneca and Teva, as well as research institutions, to discover and advance novel therapeutics. The platform is designed for drug developers, researchers, and decision-makers who need to reduce risk, accelerate progress, and bring better therapies to patients faster.

Key Solutions and Capabilities

Immunai supports critical decision-making across three core areas:

• Target Discovery: Identify novel, high-impact targets linked to disease mechanisms
• Preclinical Evaluation: Prioritize the most promising drug candidates for development using data-driven insights
• Clinical Trial Optimization: Better understand drug mechanism of action, identify optimal patient populations, and design treatment strategies to maximize trial success

How It Works: End-to-End AI Workflow

Immunai's platform transforms complex therapeutic questions into clear recommendations through a five-stage process:

1. Generate: Produce high-quality, multiomic data from clinical and preclinical samples using advanced wet lab and computational pipelines, transformed into uniform single-cell data with exceptional resolution
2. Augment: Enrich generated data with AMICA, the world's largest immune-focused, harmonized single-cell database, integrating vast immune knowledge for deeper analytical power
3. Compute: Apply advanced machine learning to compute novel immune features, linking immune mechanisms to treatment responses and outcomes
4. Validate: Use functional genomics to validate ML-driven hypotheses in the lab, ensuring robust and actionable insights
5. Recommend: Deliver clear, actionable paths forward through a recommendation engine that increases confidence in decision-making

Real-World Impact

Immunai has demonstrated success in high-stakes collaborations, including IBD target discovery with AstraZeneca and vitiligo disease mechanism and biomarker discovery for Teva's IL15 targeted antibody. The platform addresses the fundamental challenge of drug development: making critical decisions at every step with limited information and high stakes.